EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia

Andrea Mayo, Hanna Stewart, Tongtong Li iD, Cameron Penny, Rachel Hemsworth, Ashley Drohan, Katerina Neumann iD, Boris Gala-Lopez, Richard T Spence, Gregory Knapp iD

Current Oncology · 02.06.2026 · 33 (6) · 332

DOI: 10.3390/curroncol33060332 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Current Oncology, online erschienen am 02.06.2026. Verfasst von Andrea Mayo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Breast Health Research Unit, Izaak Walton Killam Health Centre, Halifax, NS B3K 6R8, Canada. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Guideline Adherence, Neoadjuvant Therapy. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: J & W Murphy Foundation, J & W Murphy Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systematic neoadjuvant therapy (NAT) is recommended for triple-negative (TNBC) and HER2+ breast cancers when tumor size at diagnosis is ≥2 cm. This study aimed to determine the proportion of patients in Nova Scotia with non-metastatic, incident, ≥2 cm TNBC and HER2+ breast cancer who received guideline-concordant NAT, stratified by administrative zone.

Methods

This retrospective analysis utilized data from the Nova Scotia Breast Screening Program. Adult patients (18–80 years) with an incident, non-metastatic, ≥T2 breast cancer diagnosis between 2021 and 2023 were considered theoretically eligible for NAT, defined by a wait time of ≥4 months between core biopsy and surgery. Guideline-concordant care was confirmed through chart review and compared across health system administrative zones and over time.

Results

Of the 291 women theoretically eligible for NAT, 67.0% received it. Significant differences in NAT receipt were observed across administrative zones (Central 73.1%, Eastern 72.9%, Northern 57.4%, Western 54.2%, p = 0.030).

Conclusions

This study identifies meaningful regional disparities in NAT receipt for TNBC and HER2+ breast cancer in Nova Scotia. Targeted strategies to improve guideline concordance are warranted and may lead to better patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesGuideline AdherenceNeoadjuvant TherapyFemaleHumansNova ScotiaMiddle AgedRetrospective StudiesAgedAdultAged, 80 and overYoung AdultAdolescent

Stichwörter der Autor:innen

HER2neoadjuvant therapypathologic complete responsetriple-negative breast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Breast Health Research Unit, Izaak Walton Killam Health Centre, Halifax, NS B3K 6R8, Canada.
  • Department of Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
  • General Surgery Research Collaborative, Dalhousie University, Halifax, NS B3H 4R2, Canada.

ORCID-Profile: Tongtong Li, Katerina Neumann, Gregory Knapp

Förderung

  • J & W Murphy Foundation
  • J & W Murphy Foundation

Zitieren

APA

Mayo, A., Stewart, H., Li, T., Penny, C., Hemsworth, R., Drohan, A., Neumann, K., Gala-Lopez, B., Spence, R. T., & Knapp, G. (2026). Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia. Current Oncology, 33(6), 332. https://doi.org/10.3390/curroncol33060332

Vancouver

Mayo A, Stewart H, Li T, Penny C, Hemsworth R, Drohan A, et al. Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia. Current Oncology. 2026;33(6):332. doi:10.3390/curroncol33060332

BibTeX
@article{Mayo2026,
  author = {Mayo, Andrea and Stewart, Hanna and Li, Tongtong and Penny, Cameron and Hemsworth, Rachel and Drohan, Ashley and Neumann, Katerina and Gala-Lopez, Boris and Spence, Richard T and Knapp, Gregory},
  title = {Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {6},
  pages = {332},
  doi = {10.3390/curroncol33060332}
}
Kostenlos starten →